|
|
xvii | |
Abbreviations |
|
xxi | |
|
X-ray crystallographic studies of protein-ligand interactions |
|
|
1 | (98) |
|
|
|
|
|
|
1 | (1) |
|
Crystallization of proteins and complexes for X-ray analysis |
|
|
1 | (18) |
|
|
1 | (3) |
|
Crystallization of proteins |
|
|
4 | (1) |
|
|
5 | (10) |
|
Crystal mounting for X-ray data collection |
|
|
15 | (1) |
|
|
16 | (1) |
|
Protein-ligand complex crystals |
|
|
17 | (2) |
|
Crystal geometry and symmetry |
|
|
19 | (10) |
|
|
19 | (8) |
|
Symmetry elements, crystal systems, and space groups |
|
|
27 | (2) |
|
X-ray diffraction from crystals |
|
|
29 | (8) |
|
Bragg's treatment of X-ray diffraction: the location of diffraction maxima |
|
|
29 | (2) |
|
The reciprocal lattice concept defining the location of diffraction maxima |
|
|
31 | (2) |
|
The structure factor F(hkl): X-ray intensities I(hkl) |
|
|
33 | (3) |
|
Calculated structure factors and R-factors |
|
|
36 | (1) |
|
Recording and measurement of X-ray diffraction patterns |
|
|
37 | (9) |
|
|
37 | (1) |
|
Recording and measuring intensity data |
|
|
38 | (5) |
|
Image plate data processing |
|
|
43 | (3) |
|
|
46 | (6) |
|
Determination of unit cell and space group |
|
|
46 | (2) |
|
|
48 | (1) |
|
Number of reflections in the data set |
|
|
48 | (1) |
|
Completeness of a data set at a given resolution |
|
|
48 | (1) |
|
|
49 | (1) |
|
Number of molecules per unit cell |
|
|
49 | (3) |
|
Electron density: reconstruction of the molecular structure |
|
|
52 | (3) |
|
|
52 | (1) |
|
Properties of the electron density |
|
|
52 | (1) |
|
Complementarity of the structure factor F(hkl) and electron density p(x, y, x) |
|
|
53 | (1) |
|
Difference electron density functions |
|
|
53 | (1) |
|
Patterson's Fourier series: the Patterson function P(uvw) |
|
|
53 | (2) |
|
Properties of the Patterson function |
|
|
55 | (1) |
|
Determination of the phases &phis;(hkl) for protein crystals |
|
|
55 | (19) |
|
|
55 | (1) |
|
Isomorphous replacement (IR) |
|
|
56 | (1) |
|
Heavy atoms and compounds for isomorphous replacement |
|
|
56 | (1) |
|
Preparation and screening of heavy atom derivatives |
|
|
56 | (1) |
|
Phase determination in single isomorphous replacement (SIR) |
|
|
57 | (1) |
|
Location of the heavy atoms |
|
|
58 | (1) |
|
Phase determination in multiple isomorphous replacement (MIR) |
|
|
58 | (2) |
|
Molecular replacement (MR)---the Sledgehammer |
|
|
60 | (11) |
|
Use of phase information and density modification |
|
|
71 | (3) |
|
What to do once phasing is acceptable |
|
|
74 | (1) |
|
Structure refinement, ligand fitting, and geometry verification |
|
|
74 | (6) |
|
|
74 | (1) |
|
Fourier refinement and simulated annealing |
|
|
75 | (2) |
|
|
77 | (3) |
|
Examples of protein-ligand complex studies |
|
|
80 | (13) |
|
N-acetyl-DL-homocysteinyl ribonuclease derivatives: protein-ligand covalent modification |
|
|
80 | (1) |
|
Environment of the SO42- ion and solvent waters in native bovine RNase A active site at 0.9 A resolution (18) |
|
|
81 | (1) |
|
Enzyme-inhibitor interactions (non-covalent): r-rat RNase A binding with 2'-5-CpG (85) |
|
|
82 | (1) |
|
Protein-carbohydrate interactions: the non-covalent sugar binding sites in the lectin MLI |
|
|
83 | (3) |
|
Glycoproteins: covalently bound sugars and the [... Asn, X, Ser/Thr...] binding site; MLI B-chain Asn 136 sugar binding site (89) |
|
|
86 | (1) |
|
Protein-steroid interactions: Fab' fragment of antibody DB3 bound to progesterone and progesterone-like steroids |
|
|
86 | (5) |
|
Protein-nucleic acid interactions: procaryotic recognition of helix-turn-helix motifs in DNA (117) |
|
|
91 | (2) |
|
Further recommended reading and software |
|
|
93 | (6) |
|
Protein-peptide interactions: cyclophilin/cyclosporin complexes |
|
|
93 | (1) |
|
Protein-protein interactions (e.g. protein-antibody): camel VH with lysozyme |
|
|
93 | (1) |
|
|
93 | (1) |
|
|
93 | (1) |
|
|
93 | (1) |
|
|
93 | (1) |
|
Software for data processing |
|
|
94 | (1) |
|
Software for Fourier and structure factor calculations |
|
|
94 | (1) |
|
|
94 | (1) |
|
Software for packing and molecular geometry |
|
|
94 | (1) |
|
Software for graphics and model building |
|
|
94 | (1) |
|
Software for molecular graphics and display |
|
|
94 | (1) |
|
|
94 | (1) |
|
Software for molecular dynamics and minimization |
|
|
94 | (1) |
|
|
94 | (1) |
|
|
95 | (4) |
|
|
99 | (24) |
|
|
|
|
|
|
99 | (1) |
|
Protein structure prediction |
|
|
100 | (4) |
|
|
101 | (1) |
|
Threading, or fold recognition techniques |
|
|
101 | (1) |
|
Homology (or comparative) modelling |
|
|
101 | (3) |
|
Analysis of protein structures |
|
|
104 | (1) |
|
Docking of ligands to proteins |
|
|
105 | (4) |
|
Ab initio (de novo) ligand design |
|
|
109 | (5) |
|
|
110 | (1) |
|
|
111 | (1) |
|
|
112 | (2) |
|
Calculation of binding energies |
|
|
114 | (2) |
|
Statistical analysis of a set of protein ligands |
|
|
116 | (1) |
|
|
117 | (6) |
|
|
117 | (1) |
|
|
117 | (6) |
|
|
123 | (46) |
|
|
|
|
|
|
123 | (3) |
|
The ordinary absorption of light |
|
|
126 | (2) |
|
The spectroscopic basis of circular dichroism |
|
|
128 | (4) |
|
The circular dichroism spectrometer |
|
|
132 | (4) |
|
The merits and uses of CD spectroscopy |
|
|
136 | (2) |
|
Protein/peptide conformations as studied by CD spectroscopy |
|
|
138 | (7) |
|
Instrumental measurement factors |
|
|
143 | (1) |
|
|
143 | (1) |
|
|
144 | (1) |
|
Monitoring ligand binding by CD spectroscopy |
|
|
145 | (7) |
|
Measurement conditions and instrumental parameters |
|
|
146 | (1) |
|
Further aspects of the concentration used for absorption and CD measurements |
|
|
147 | (5) |
|
Analysis of CD ligand binding titration studies |
|
|
152 | (12) |
|
|
153 | (2) |
|
|
155 | (2) |
|
|
157 | (1) |
|
|
157 | (3) |
|
The effect of concentration on binding constant determination |
|
|
160 | (4) |
|
CD kinetics---drug binding to proteins |
|
|
164 | (5) |
|
|
166 | (3) |
|
Generic techniques for fluorescence measurements of protein-ligand interactions; real time kinetics and spatial imaging |
|
|
169 | (32) |
|
|
|
|
|
|
|
|
|
|
169 | (2) |
|
Ligand-protein interactions revealed by intrinsic (tryptophan) fluorescence |
|
|
171 | (1) |
|
Tryptophan fluorescence measurements to demonstrate ligand-protein interactions |
|
|
172 | (3) |
|
Steady state tryptophan fluorescence quenching |
|
|
172 | (1) |
|
Time-resolved fluorescence lifetime and anisotropy decay measurements of albumin |
|
|
172 | (3) |
|
The surface electrostatic potential: one of the trinity of electrical membrane potentials |
|
|
175 | (1) |
|
Membrane electrostatics: implementation of fluoresceinphosphatidylethanolamine (FPE) to measure ligand-receptor interactions of membranes |
|
|
175 | (4) |
|
Labelling human cells with FPE |
|
|
178 | (1) |
|
Location of FPE in the membrane |
|
|
178 | (1) |
|
Digital imaging: using CCD fluorescence microscopy and confocal scanning laser fluorescence microscopy (CSLM) of ligand binding reactins of living cells |
|
|
179 | (1) |
|
Fluorescent images corrected for probe disposition and photobleaching |
|
|
180 | (2) |
|
Spatial imaging of the cell surface to identify localized ligand binding |
|
|
182 | (1) |
|
|
182 | (7) |
|
|
189 | (9) |
|
Ligand (oleate) binding to HAS revealed by tryptophan fluorescenece quenching |
|
|
189 | (1) |
|
Kinetics of oleate-dependent fluorescence changes of HSA |
|
|
190 | (1) |
|
Interactions of a signal peptide (p25) with model membranes |
|
|
190 | (3) |
|
The interactions of serum albumin with B and T lymphocytes |
|
|
193 | (1) |
|
Receptor-mediated membrane binding of albumin |
|
|
193 | (2) |
|
Influence of interleukin-8 (IL-8) on the interaction of the gp41 fusion domain of HIV with T lymphocytes |
|
|
195 | (1) |
|
The interaction of Alzheimer's peptides with B12 microgial cells |
|
|
196 | (2) |
|
Quantitation of spatially localized interactions of ligands (albumin) with living cells |
|
|
198 | (1) |
|
|
198 | (3) |
|
|
199 | (1) |
|
|
199 | (2) |
|
|
201 | (38) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
201 | (1) |
|
First- and second-order reactions |
|
|
202 | (4) |
|
First-order irreversible reactions |
|
|
202 | (1) |
|
Second-order irreversible reaction |
|
|
203 | (1) |
|
First-order reversible reaction |
|
|
204 | (1) |
|
Second-order reversible reactions |
|
|
204 | (2) |
|
Principle of operation of the stopped-flow instrument |
|
|
206 | (2) |
|
Testing the performance of a stopped-flow instrument |
|
|
208 | (4) |
|
|
208 | (1) |
|
|
208 | (2) |
|
|
210 | (2) |
|
Optimization of instrument |
|
|
212 | (4) |
|
|
212 | (1) |
|
|
212 | (1) |
|
Choice of emission filter |
|
|
213 | (1) |
|
|
214 | (1) |
|
|
215 | (1) |
|
Probes to monitor stopped-flow reactions |
|
|
216 | (2) |
|
|
216 | (1) |
|
|
217 | (1) |
|
Measurement of association and dissociation rate constants |
|
|
218 | (4) |
|
|
218 | (1) |
|
|
219 | (1) |
|
|
219 | (1) |
|
Example of determination of association and dissociation rate constants |
|
|
220 | (1) |
|
Kinetics of interaction of a non-fluorescent ligand with a protein |
|
|
220 | (2) |
|
Complex binding reactions |
|
|
222 | (1) |
|
|
222 | (9) |
|
|
223 | (1) |
|
|
223 | (1) |
|
|
224 | (1) |
|
|
224 | (2) |
|
|
226 | (5) |
|
Modern continuous flow techniques |
|
|
231 | (1) |
|
|
231 | (8) |
|
Strengths and limitations |
|
|
232 | (1) |
|
Example: myosin-subfragment 1.ADP binding to pyrene-actin |
|
|
232 | (4) |
|
|
236 | (1) |
|
|
237 | (2) |
|
Protein-ligand interactions studied by FTIR spectroscopy: methodological aspects |
|
|
239 | (26) |
|
|
|
|
|
|
|
|
|
|
239 | (1) |
|
Protein structure determination by FTIR spectroscopy |
|
|
240 | (2) |
|
|
242 | (14) |
|
|
242 | (5) |
|
Experimental conditions: choice of solvent |
|
|
247 | (3) |
|
Solvent and water vapour subtraction |
|
|
250 | (3) |
|
Derivation and deconvolution |
|
|
253 | (3) |
|
Thermal and solvent manipulation techniques for assessing protein-ligand interactions |
|
|
256 | (4) |
|
|
260 | (1) |
|
Isotope edited difference spectroscopy |
|
|
260 | (1) |
|
Reaction-induced difference spectroscopy |
|
|
261 | (4) |
|
|
262 | (3) |
|
Protein-ligand interactions studied by Raman and resonance Raman spectroscopy |
|
|
265 | (46) |
|
|
|
|
|
|
265 | (3) |
|
|
268 | (24) |
|
Visible/near infrared Raman spectroscopy |
|
|
268 | (7) |
|
|
275 | (2) |
|
Difference Raman spectroscopy |
|
|
277 | (2) |
|
Resonance Raman spectroscopy |
|
|
279 | (6) |
|
Ultra-violet Raman and ultra-violet resonance Raman (UVRR) spectroscopy |
|
|
285 | (1) |
|
Raman optical activity (ROA) |
|
|
286 | (2) |
|
Time-resolved resonance Raman (TR3) spectroscopy |
|
|
288 | (1) |
|
Surface-enhanced Raman spectroscopy (SERS) and surface-enhanced resonance Raman spectroscopy (SERRS) |
|
|
289 | (2) |
|
Coherent anti-Stokes Raman spectroscopy (CARS) |
|
|
291 | (1) |
|
Interpretation of protein spectra and band assignments |
|
|
292 | (3) |
|
|
292 | (3) |
|
Group frequencies of side groups |
|
|
295 | (1) |
|
Specific information on proteins and their interactions with ligands |
|
|
295 | (16) |
|
|
295 | (3) |
|
Solvent exposure of aromatic side chains |
|
|
298 | (1) |
|
pKD's of protein-ligand complexes |
|
|
299 | (1) |
|
pKa's of specific protein groups |
|
|
299 | (1) |
|
Entropic and enthalpic changes on ligand binding |
|
|
300 | (2) |
|
|
302 | (4) |
|
|
306 | (1) |
|
|
307 | (4) |
|
Electrospray ionization mass spectrometry |
|
|
311 | (36) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
311 | (1) |
|
|
311 | (2) |
|
|
313 | (14) |
|
|
313 | (4) |
|
|
317 | (1) |
|
|
318 | (2) |
|
|
320 | (1) |
|
Mass analysis---selection and detection |
|
|
320 | (3) |
|
|
323 | (4) |
|
|
327 | (1) |
|
Protein-ligand interactions of calmodulin |
|
|
327 | (20) |
|
Preparation of calmodulin |
|
|
327 | (1) |
|
ESI mass spectrometry of calmodulin |
|
|
328 | (16) |
|
|
344 | (3) |
|
Nitroxide spin labels as paramagnetic probes |
|
|
347 | (36) |
|
|
|
|
|
|
347 | (1) |
|
Origin of the EPR spectrum |
|
|
348 | (10) |
|
|
348 | (1) |
|
|
349 | (1) |
|
Phase-sensitive detection and the first derivative spectrum |
|
|
350 | (1) |
|
|
351 | (2) |
|
EPR spectroscopy of nitroxide spin labels |
|
|
353 | (5) |
|
Conventional EPR spectroscopy |
|
|
358 | (12) |
|
|
358 | (2) |
|
Modification of protein side groups |
|
|
360 | (8) |
|
Analysis of multiple component spectra |
|
|
368 | (2) |
|
|
370 | (7) |
|
|
370 | (1) |
|
|
371 | (1) |
|
|
372 | (3) |
|
Interpretation of ST-EPR spectra |
|
|
375 | (2) |
|
Protein-ligand interactions |
|
|
377 | (6) |
|
|
377 | (3) |
|
Time-resolved spectroscopy |
|
|
380 | (1) |
|
|
380 | (3) |
|
NMR studies of protein-ligand interactions |
|
|
383 | (24) |
|
|
|
|
|
|
383 | (1) |
|
Preparation of sample and preliminary binding studies |
|
|
384 | (1) |
|
Chemical exchange and analysing the NMR spectra for protein-ligand complexes |
|
|
385 | (3) |
|
Screening for ligand interactions |
|
|
388 | (2) |
|
Overview of NMR techniques used to study protein-ligand interactions |
|
|
390 | (2) |
|
Exchange rate measurements |
|
|
392 | (3) |
|
|
395 | (2) |
|
Protein resonance assignments |
|
|
395 | (1) |
|
Ligand resonance assignments |
|
|
396 | (1) |
|
|
397 | (10) |
|
|
398 | (2) |
|
Nuclear Overhauser effects and structure calculations |
|
|
400 | (1) |
|
Determination of ionization states |
|
|
401 | (1) |
|
Protein ionization states |
|
|
402 | (3) |
|
|
405 | (2) |
|
Quantification and mapping of protein-ligand interactions at the single molecule level by atomic force microscopy |
|
|
407 | (18) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
407 | (3) |
|
|
410 | (1) |
|
Quantification of the adhesion forces of individual protein-ligand complexes |
|
|
410 | (11) |
|
|
410 | (2) |
|
Measurement of antibody-antigen interactions |
|
|
412 | (9) |
|
Spatial mapping of protein-ligand interactions |
|
|
421 | (1) |
|
|
421 | (4) |
|
|
422 | (3) |
List of suppliers |
|
425 | (8) |
Index |
|
433 | |